Elsalys Biotech: New Studies Confirm Anti-CD160 Potential in Ophthalmology

Source: Elsalys Biotech

Elsalys Biotech, announced the publication of two studies validating the potential of its first-in-class anti-CD160 antibodies for the treatment of neovascular diseases of the eye.

The first study reveals that in patients, CD160 endothelial expression in retinal vessels is higher and correlates with a wide range of ocular neovascular diseases, while the second reports the safety of the antibody and demonstrates, in relevant animal models, its therapeutic benefit alone and in combination with anti-VEGF agents, the current standards of care for retinal vascular pathologies.

Published in Investigative Ophthalmology & Visual Science, the results of these two studies confirm Elsalys Biotech’s preclinical data in ophthalmology: CD160 antibodies could be used (i) for its additive or synergistic effect with the current standard of care, or (ii) as alternative therapies in patients with anti-VEGF-resistant or refractory neovascular diseases.

CD160: a first-in-class target for the treatment of retinal neovascular diseases

CD160 was already known to be a marker of activated endothelial cells that surround newly formed blood vessels, and as such is considered a potential target for the treatment of diseases associated with neoangiogenesis. Henry et al. have now studied CD160 expression in the human eye and find that it is actually expressed mainly in endothelial cells and across some other cell types. Importantly, they reveal that its levels of expression are significantly higher in the retina of patients suffering from a range of ocular neovascular diseases, strongly supporting that CD160 could well represent an interesting target for novel anti-angiogenic therapies for these patients.

Anti-CD160 is a potent inhibitor of ocular vascularization, both alone and in combination with anti-VEGF treatment

Previous studies had shown that the engagement of CD160 by an activating antibody induces cell death of endothelial cells that surround newly formed blood vessels, thereby blocking their formation, both in vitro and in vivo. In the second publication, Menguy et al. assessed the efficacy of this antibody as a monotherapy or as a combination therapy with bevacizumab, a monoclonal antibody that targets the VEGF. They show that administration of an anti-CD160 has an antiangiogenic effect in vivo in a relevant model of corneal neovascularization. This effect is equivalent to that seen with bevacizumab (Figure 1A) or with aflibercept, a drug that also inhibits the VEGF pathway.

The antiangiogenic effect of the combination treatment (anti-CD160 and bevacizumab) was significantly higher than either antibody alone, strongly arguing that the anti-CD160 (i) may act independently of the VEGF pathway and (ii) could be a good alternative for patients that poorly respond to an anti-VEGF treatment.

Interestingly, the additive effect observed upon treatment with CL1-R2 in combination with bevacizumab in the CNV rabbit model suggests that both CD160 and VEGF pathways contribute to the efficacy observed, and that the two mAbs probably act via different pathways. This could result in new therapeutic opportunities for co-targeted or combination therapies alongside anti-VEGFs.

Anti-CD160 is safe and efficacious in primate

Efficacy of anti CD160 was then confirmed on choroidal neovascularisation in the most relevant primate model. Beyond the efficacy data, the CD160 antibody causes no treatment-related adverse effects in the most relevant animal model of wAMD, (a primate model of laser-induced choroidal neovascularisation), confirming the safety of targeting CD160 when treating retinal neovascular diseases.

 “These results demonstrate that a combination with anti-CD160 provides a tangible alternative to patients suffering from neovascular diseases of the eye,” explains Christine Guillen, CEO and Co-founder, Elsalys Biotech. “With these positive results in hand, we are excited to move forward towards a first clinical trial with CD160 antibody in ophthalmology and confident in the continuation of the program with our partner THEA laboratories that could exercise the option taken in February 2018 on ELB011 before end of 2018.”


Recent Content